Compare Acadia Healthcare Company Inc (ACHC) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Acadia Healthcare Company Inc trades at $31.88 (market cap $2.90B), while Alnylam Pharmaceuticals, Inc. trades at $222.57 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.2× Acadia Healthcare Company Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ACHC | ALNY | |
|---|---|---|
Market Cap | $2.90B | $29.60B |
Sector | Health | Health |
52-Week High | $35.61 | $491.22 |
52-Week Low | $11.68 | $205.48 |
Enterprise Value | $5.29B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.14, down 2.01% today, with a neutral technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains a net loss of -$1.10B for 2025. Analyst consensus is bullish with a $36.00 price target, though ongoing legal investigations and negative profit margins present headwinds. Cash flow from operations improved to $211M in 2026, supporting operational stability amid challenges.
The outlook for ACHC hinges on execution of its turnaround strategy and resolution of legal issues. Upside potential exists if EBITDA guidance improvements and admissions growth persist, but risks from litigation and sustained losses warrant caution. The stock's current valuation at a P/E of 19.82 and P/S of 0.84 may attract value investors if profitability recovers.
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
